F-18-FDG PET/CT findings of paraneoplastic dermatoses

Kazuyoshi Suga

Abstract

Paraneoplastic dermatoses (PD) are defined as nonspecific skin disorders which are associated with internal neoplasms, but without direct association to primary tumors or metastases. Recognition of PD and the following surveillance may lead to the diagnosis of internal malignant neoplasms including early stage ones. Accurate imaging examinations in the following searching is essential in identifying the underlying neoplasms. Since whole-body 18-fluoro-2-deoxyglucose (F-18-FDG)-positron emission (PET)/computed tomography (CT) has been widely used in early diagnosis, staging of various malignant tumors, it may play a role for detection of underlying or occult malignant neoplasms in patients with PD. However, to date, only a few reports of FDG PET/CT findings of the associated neoplasms in PD patients have been cited in the literature. The present paper shows the cases of FDG-avid associated neoplasms in patients with PD in our 10-year experience in our institute, and reviews the well-known and/or relatively common PD and their associated neoplasms, and the previously reported cases of FDG-avid associated neoplasms in these patients.

Keywords Paraneoplastic dermatoses · F-18-FDG PET/CT · Malignant tumors

Introduction

Paraneoplastic syndromes are defined as clinical syndromes involving non-metastatic systemic effects that accompany malignant diseases [1–3]. These syndromes are collections of symptoms that result from substances produced or induced by the tumor, and they occur remotely from the tumor itself [1]. They are consisted of heterogeneous disorders that can affect any organ system including the central and peripheral nervous systems as well as the musculoskeletal, dermatologic, hematologic, endocrine, or gastrointestinal systems [1–3]. Among these disorders, paraneoplastic dermatoses (PD) are generally defined as nonspecific skin disorders which are associated with internal neoplasms [4–9]. PD are relatively rare, acquired diseases, and to date, over 50 PD have been reported [8]. PD may be caused by a variety of factors related to the internal neoplasms, such as polypeptides, hormones, cytokines, antibodies or growth factors that act as mediators, interfering with cell communication [4–9]. As well as other paraneoplastic syndromes, PD can be potential markers or a warning sign of internal or occult malignancy. Recognition of PD and the following surveillance may lead to the early diagnosis of internal malignancy and a better prognosis, since PD occasionally precede underlying neoplasms. Whole-body 18-fluoro-2-deoxyglucose (F-18-FDG)-positron emission (PET)/computed tomography (CT) can detect the various malignant tumors with increased cellular metabolism by showing high FDG uptake even in patients with cancer of unknown primary origin, and may also contribute to the detection of underlying neoplasms in patients with PD. Although the previous investigators have shown some promising results in the role of whole-body FDG PET/CT in the workup of patients with suspected internal neoplasms and paraneoplastic syndromes [1–3], to date, only a few reports of FDG-avid-associated neoplasms in PD patients have been cited in the literature. This paper shows the cases of FDG-avid-associated neoplasms in PD patients which were experienced during the past 10 years in our institute, and also reviews the well-known and/or relatively common PD and their associated neoplasms based on the literature, and the previously reported cases of FDG-avid-associated neoplasms in PD patients.
Classification of PD

Based on pathological aspect, PD can be classified in papulosquamous disorders, interface dermatitis, reactive erythema, neutrophilic dermatosis, dermal proliferating disorder, deposition disorder and others (Table 1) [4–9]. Based on the frequency in which PD is associated with neoplasms, PD are classified in two groups: obligate PD, in which the associated neoplasm is present in 90–100% of the cases, and facultative PD, in which the neoplasm can be detected in 25–30% of the cases [5]. There are also some other skin diseases which the clinicians frequently encounter and could be associated with underlying neoplasms, but with less associative strength compared with other PD [5, 7, 9]. In this paper, we describe PD according to the frequency in which PD is associated with underlying neoplasms, and also briefly describe other common skin diseases which could be classified as PD in a broad sense.

Obligate PD

Acanthosis nigricans

Acanthosis nigricans (AN) typically develops suddenly in people over 40 years of age as symmetrical hyper-pigmentation in intertriginous areas, without differences by sex [5, 9–14]. AN is characterized by extensive condition, progressive course, pruritic, hyper-keratotic, and hyper-pigmented plaques with a subsequent formation of velvety papillomas, and the lesions are frequently involved in the skin wrinkles of the neck, armpits, groin, and axillary region [14]. AN often precedes or occurs simultaneously with the diagnosis of cancer. AN is most frequently associated with intra-abdominal carcinomas (73.2%), including gastric adenocarcinoma and other tumors in the liver, uterus/cervix, breast, lung, pancreas, and colon/rectum [5, 11]. In Japan, the frequency of gastric cancer is higher (more than 90%) compared with western countries [10]. Currently, the pathogenesis is proposed that certain cytokines produced by the tumor, such as transforming growth factor alpha, insulin-like growth factor 1, and fibroblast growth factor, participate in the development of the lesions in AN through the stimulation of keratinocytes, melanocytes, and fibroblasts [5, 14].

Table 1  Classification of PD based on pathological aspect

| Paraneoplastic dermatoses       | Associated neoplasms                                                                 |
|--------------------------------|-------------------------------------------------------------------------------------|
| Papulosquamous disorder        |                                                                                     |
| Acanthosis nigricans           | Gastric, esophageal, pancreatic, liver and bile duct adenocarcinomas                 |
| Acquired pachydermatoglyphia    | Gastric and pulmonary carcinomas, esophageal carcinomas                              |
| Leser–Trélat sign              | Gastric and colorectal adenocarcinomas, esophagus, duodenum, pancreas, gallbladder and liver carcinomas |
| Bazex syndrome                 | Aerodigestive tract carcinomas (oral cavity, larynx, pharynx, trachea, esophagus and lung) |
| Interface dermatitis           |                                                                                     |
| Paraneoplastic pemphigus       | Non-Hodgkin lymphoma, chronic lymphocytic leukemia, Castleman’s disease, and thymoma |
| Paraneoplastic dermatomyositis | Lower respiratory, gastrointestinal tract and ovarian carcinomas                      |
| Reactive erythema              |                                                                                     |
| Necrolytic migratory erythema  | Glucagonoma                                                                         |
| Erythema gyratum repens        | Pulmonary, esophageal and breast carcinomas                                         |
| Neutrophilic dermatosis        |                                                                                     |
| Pyoderma gangrenosum           | Myelodysplastic syndrome, myeloma, and leukemia                                      |
| Sweet syndrome                 | Myeloproliferative and lymphoproliferative disorders, and colorectal carcinomas      |
| Dermal proliferating disorder  |                                                                                     |
| Multicentric reticulum hystiocytosis | Gastric, ovarian, breast and uterine carcinomas, myeloma, melanoma and lymphoma   |
| Necrotic xanthgranuloma         | Multiple myeloma and chronic myelomonocytic leukemia                                  |
| Deposition disorder            |                                                                                     |
| Scleromyxedema                 | Multiple myeloma, Waldenström macroglobulinemia, Hodgkin and non-Hodgkin lymphomas, leukemia and thymic carcinoma |
| Cutaneous amyloidosis          | Multiple myelomas                                                                    |
| Others                         |                                                                                     |
| Acquired hypertricosis lanuginose | Colorectal, pulmonary and breast carcinomas                                      |
There is a case report of FDG-avid esophageal cancer detected by FDG PET/CT in a patient with AN [10]. The reported patient underwent FDG PET/CT subsequently after the diagnosis of AN, which showed an intense FDG uptake in the esophagus without any FDG-avid lymph nodes. The surgery revealed esophageal squamous cell carcinoma at the pathological stage of T3, N0 and M0. It is noteworthy that the dermal thickening and the pigmentation of AN were completely relieved at 6 months after the surgery in this patient.

**Acquired pachydermatoglyphia, Acquired palm keratosis// Tripe palms, Leser-Trélat Sign**

Acquired pachydermatoglyphia (AP) or acquired palm keratosis/tripe palms is dermatose that presents as hyperkeratosis of the palms and soles, with male predominance [8, 15–18]. AP is characterized by yellowish, velvety, diffuse palmar hyperkeratosis, with accentuated dermatoglyphic patterns, that resembles the intestinal mucosa. Pathologically, acanthosis, hyperkeratosis, and perivascular deposition of mucin in the dermis is shown. AP is usually associated with Leser–Trélat sign (LTS) described later and AN. Neoplastic processes have been reported in 90% of cases of AP, including gastric and lung cancers (50%) and breast and genitourinary tract cancers [8]. Physiologically, a pivotal role of epidermal growth factor-α and transforming growth factor-α released by neoplastic cells has been reported.

LTS shows a rapid appearance of multiple seborrheic keratoses on the thorax and dorsum, and occurs equally in men and women, and at an average age of 61 years [8, 15]. Approximately half of all cancers associated with LTS are adenocarcinomas, present in the gastrointestinal tract in 32% of cases [8]. Lymphoproliferative abnormalities are associated in 21% of cases. Because keratoses are benign and a common occurrence in older people, it is often ignored. It has been recommended that all patients with LTS should be screened for neoplasms [8, 15].

There is a case report of FDG-avid mediastinal squamous cell carcinoma detected by FDG PET/CT in a patient with LTS [15]. This patient had a hypermetabolic lesion in the region of the aortic arch on the mediastinal mass on FDG PET/CT, which was later pathologically diagnosed as a primary keratinizing squamous cell carcinoma of the lung.

**Acrokeratosis paraneoplastica of Bazex (Bazex syndrome)**

Bazex syndrome is characterized by psoriasiform changes on the digits, and in some patients spread to the ears, nose and in later stages to the limbs and trunk [8, 16–18]. This paraneoplastic process predominates in men with an average age of 40 years. As the disease progresses, desquamation affects the dorsal and palmoplantar regions producing a violaceous keratoderma. All the cases cited in the literature were associated with malignancy. Skin manifestations often precede the diagnosis of cancer in approximately 2–6 months in 65–70% of patients. About 80% of cases are associated with a squamous cell carcinoma of the upper aero-digestive tract [15, 16]. As the pathogenesis, the crossed reactions between tumor antigens and growth factor receptors on epidermal cells and/or the cutaneous changes by the action of epidermal growth factor, transforming growth factor alpha and insulin-like growth factor secreted by the tumor cells are proposed [15, 16].

There are case reports of FDG-avid nodular sclerosing Hodgkin disease and lung cancer in patients with Bazex syndrome [17, 18]. One of these patients showed diarrhea and weight loss, a colonoscopy was initially performed but it was normal. Subsequent FDG PET/CT revealed multiple FDG-avid retroperitoneal lymphadenopathies, which were diagnosed as nodular sclerosing Hodgkin disease by a function of these lymphadenopathies. It is noteworthy that after two rounds of chemotherapy, the skin symptoms of Bazex syndrome had disappeared in this patient. In the other patient, FDG PET/CT showed FDG uptake in the lung tumor and mediastinal lymphadenopathy. A transbronchial biopsy of the lung tumor showed adenocarcinoma, which was diagnosed as stage IVB lung cancer.

**Paraneoplastic pemphigus**

Paraneoplastic pemphigus (PNP) is a clinically, histologically and immunologically distinct autoimmune mucocutaneous disease, and is a rare skin condition involving severe blistering of the mucus membranes, most often affects people aged 45–70 years, without gender predominance [8, 19, 20]. PNP typically presents with painful mucosal erosions and dusky patches on the skin that later desquamate. The mouth is always affected, but other regions including the lips, oropharynx, nasopharynx, conjunctivae, anogenital region, and esophagus may also be affected, after which cutaneous lesions may appear. Auto-reactive T cells and IgG autoantibodies against heterogeneous antigens, including plakin family proteins and desmosomal cadherins, contribute to the pathogenesis of PNP. Two-thirds of patients with PNP have a recognized neoplasm at the onset of PNP. Approximately 80% of the associated neoplasms are of hematological origin, such as non-Hodgkin lymphoma (42%), chronic lymphocytic leukemia (29%), Castleman disease (10%), thymoma, Waldenstrom's macroglobulinemia and follicular dendritic cell sarcoma [8].

There are several case reports of FDG-avid neoplasms (Castleman disease, mediastinal follicular dendritic cell sarcoma, and inflammatory myofibroblastic tumor) in patients with PNP [21–23]. In the case of the mediastinal sarcoma, FDG PET/CT showed intense F-FDG uptake in the primary
tumor, accompanied by parasternal FDG-avid adenopathy. The surgical pathology proved parasternal lymph node metastasis. Mediastinal follicular dendritic cell sarcoma is very rare disease, and there are only 5 reports on the PET-CT features of mediastinal follicular dendritic cell sarcoma including the reported case, whereas SUVmax ranged from 2.7 to 11.4. While the reported case of inflammatory myofibroblastic tumor showed an intense FDG uptake, FDG uptake in this tumor generally vary from low to high FDG uptake, which may be due to tumor cellularity, biological behaviors of the tumor cells, the composition and the proportion of inflammatory cells, and the extent of activation of the inflammatory cells [23]. Our case showed FDG-avid thoracic Castleman disease, also with FDG-avid cutaneous PNP lesions (Fig. 1). FDG-avid cutaneous PNP lesion has not yet been described in the previous literature. As the presence of inflammatory cells in the cutaneous PNP lesion has been reported as one of the major histological features [8, 19, 20], FDG uptake by these inflammatory cells may cause FDG avidity in the cutaneous lesions.

**Necrolytic migratory erythema**

In necrolytic migratory erythema (NME), initially, a pinkish, maculopapular rash with irregular edges and a standard arcuate or polycyclic pattern, prominent in areas of trauma, is observed, often affecting the knees and intertriginous areas [24]. NME can represent an early sign of pancreatic glucagonoma [24]. The pathogenesis of NME has been reported that the reduced level of zinc and amino acids caused by tumor metabolism could determine an increase in arachidonic acid production, leading to cutaneous inflammation.

There is a case report of FDG-avid pancreatic glucagonoma on FDG PET/CT in a patient with NME [25]. In the reported case, mild FDG uptake with SUVmax of 2.3 was seen in the tumor.

![Fig. 1](image-url)  
Cutaneous manifestation of paraneoplastic pemphigus at the hand in a 45 year-old female who presented with oral mucosal and lip lesions and polymorphous cutaneous eruption including the both hands and feet (a; arrows). Whole-body FDG PET maximum projection image showed abnormal FDG uptake (SUVmax 7.3) in the mouth/lips lesions, also abnormal uptakes (SUVmax6.9) in the both hands and feet (b; arrows). Cross-sectional FDG PET/CT images showed FDG-avid (SUVmax 4.0) mass in the left thorax (arrowhead) and abnormal FDG uptakes in the lip/mouth lesions and cutaneous lesion of the feet (arrows). Later, this patient had surgical resection of the thoracic FDG-avid mass which was diagnosed as hyaline vascular-type Castleman disease.
Erythema gyratum repens

In erythema gyratum repens (EGR), the skin develops a widespread, serpiginous, polycyclic and pruriginous erythema which is desquamative around the edges, and fast-growing, producing concentric figures that resemble a wood surface that may cover much of the trunk and proximal extremities [24, 26]. ERG is seen more commonly in men, at an average age of 63 years, and malignant neoplasms are found in 82% of the patients with EGR. Lung cancer is the most common (32%), followed by cancer of the esophagus (8%) and breast (6%) [8]. Other malignancies also are associated with EGR, such as colon, stomach, bladder, prostate, uterine, rectal and pancreatic cancer and multiple myeloma [8]. The diagnosis of EGR precedes the diagnosis of the underlying neoplasms in approximately 80% of patients. As the pathogenesis of EGR, tumor antigens may form and cross-react with endogenous skin antigens or tumor products and may alter endogenous skin antigens making them susceptible to autoimmune recognition. EGR seems to be extremely rare, as a current literature search yielded a handful of additional case reports [24, 26].

There is a case report of FDG-avid T cell lymphoma on FDG PET/CT in a patient with EGR [27]. The reported patient presented with a solitary large mass with central necrosis on the occipital region, which showed abnormal FDG uptake.

Acquired hypertricosis lanuginose

Acquired hypertricosis lanuginose (AHL) is characterized by the sudden onset of thin and soft hair, lanugo-like, initially on the face predominantly in women [8, 28]. AHL is most commonly associated with adenocarcinomas of the lung and colon (27% and 24%, respectively) [8, 28]. AHL is extremely rare, and to date, a total of only 56 patients with AHL-associated neoplasms have been reported.

To our knowledge, there is no case report of FDG-avid neoplasms on FDG PET/CT in patients with AHL.

Faculative PD

Pyoderma gangrenosum (PG)

Pyoderma gangrenosum (PG) is a rare, idiopathic, inflammatory, neutrophilic dermatosis that is generally characterized by recurrent sterile skin ulceration [29]. Up to 7% of PG cases are associated with underlying hematological neoplasms, such as myelodysplastic syndrome, myeloma, and acute myelogenous leukemia [8]. In addition, it can be associated with solid organ malignancy and rectal cancer. Pathologically, non-specific neutrophilic infiltration in the dermis is observed.

There is a case report of FDG-avid lymphoma on FDG PET/CT in a patient with PG [30]. In the reported patient, FDG PET/CT exhibited a nodular mass with intense FDG uptake in the right lower lung field, and extensive and marked FDG-avid sites in multiple sites of the bones and soft tissue of the left lower leg.

Sweet syndrome

Sweet syndrome (SS) is a prototypic acute febrile neutrophilic dermatosis, clinically characterized by painful, edematous, shiny erythematous nodules or plaques, which usually occur in the head, neck, and upper limbs. Pathologically, there are diffuse neutrophilic infiltrate in the dermis, edema, and fragmentation of the nuclei of neutrophils [8, 31–33]. Paraneoplastic SS accounts approximately for 21% of total SS cases; 85% of paraneoplastic SS are associated with hematological disorders, such as acute myelogenous leukemia, myelodysplastic syndrome, Hodgkin disease and polycythemia vera. In addition, paraneoplastic SS can be associated with adenocarcinomas of the breast, genitourinary tract and gastrointestinal tract. Although the paradigm of PD is the absence of the neoplastic cells into cutaneous lesion, an exception is represented by SS associated with a hemopoietic neoplasm, where myeloid cells are often detected in the cutaneous biopsy. In paraneoplastic SS, the over-production and dysregulation of inflammatory cytokines, like interleukin, granulocyte colony-stimulating factor, and granulocyte macrophage colony-stimulating factor have been shown to be involved in the development of SS [8].

To date, the cases of FDG-avid myelodysplastic syndrome and non-Hodgkin T cell lymphoma on FDG PET/CT in patients with SS have been reported [31, 32]. In the reported patient of myelodysplastic syndrome, FDG PET/CT showed multiple cutaneous foci with increased FDG uptake throughout the body, which were some of the cutaneous erythematous nodules of SS [31]. FDG PET/CT also showed multiple FDG-avid lymph nodes in the mediastinum, bilateral pulmonary hili and abdomen, and diffusively increased FDG uptake of bone marrow. In the reported case of T cell lymphoma, FDG PET/CT showed hepatomegaly with intense FDG uptake, which was diagnosed as T cell lymphoma by a liver biopsy [32]. Our case of SS showed FDG-avid follicular lymphoma lesions and gastric cancer (Fig. 2).

Dermatomyositis

Dermatomyositis (DM) is an uncommon idiopathic, inflammatory myopathy characterized by proximal muscle weakness and cutaneous lesions. Skin lesions precede muscle involvement by months or years in more than 50% of DM patients [8, 34–42]. As cutaneous lesions, a violet-colored
or dusky red rash and a heliotrope rash develop, most commonly on face and eyelids and on knuckles, elbows, knees, chest and back. The rash can be itchy and painful. The reported rate of occurrence of malignant neoplasms in patients with DM is 15–30% [39]. Dysphagia occurs in 10–20% of patients. The risk of malignancy increases with the age of the patients, and is higher in the first year after diagnosis, then steadily decreases through five years, but remains persistently slightly elevated in comparison to the general population [8]. Predictive factors for malignant neoplasms in DM include patient age over 52 years, male gender, ulcers, skin necrosis, dysphagia, increased erythrocyte sedimentation rates, increased amounts of C-reactive protein, anti-155/140 or transcriptional intermediary factor 1 (TIF1) γ antibodies, and elevated serum creatine phosphokinase [8, 34–42]. While lung and gastrointestinal neoplasms are the mostly reported in DM patients, different malignancies including nasopharynx, ovarian, breast, prostate, kidney cancers, and different types of hematological malignancies are also reported. In Japan, gastric cancer is found in up to 25% of patients [37]. The etiopathogenesis of DM is still unclear, but recent studies have suggested that DM might arise as an autoimmune response against cancer which cross-reacts with regenerating muscle cells, as myositis-specific autoantigens are expressed in both tumor cells and undifferentiated myoblasts [34–42]. An association between autoantibody (anti-155/140 or transcriptional intermediary factor 1) IgG and paraneoplastic DM also has been described [35, 37].

Whole-body FDG PET/CT often shows symmetrical muscle hyper-metabolism representing the inflammatory nature of DM, with correlation with serum muscle enzymes in DM patients [37]. Proximal muscles of shoulders, buttocks and thigh are the most frequent FDG-positive regions. Whole-body FDG PET/CT also has the excellent diagnostic performance for simultaneously detecting and diagnosing underlying or occult malignant neoplasms in DM patients [36–42]. It is comparable to a wide panel of extensive screening investigations in ability to detect cancers, and a single FDG PET/CT scan may potentially negate the need for numerous investigations [35, 41]. In our institute, among the patients with various PD, DM patients have the most frequently undergone whole-body FDG PET/CT to search internal malignancies. In our DM patients, 12(48%) out of 25 subjects examined showed FDG-avid malignant neoplasms, including 5 colon cancers (Fig. 3), 3 lung cancers, 2 breast cancers, 1 gastric cancer, 1 gallbladder cancer (Fig. 4), 1 thyroid cancer, 1 uterine body cancer, and 1 malignant lymphoma. It is noteworthy that 3 of these patients had duplicated malignant tumors (colon and breast cancers, colon and lung cancers, and colon and thyroid cancer, respectively) (Fig. 5). Except for the patients who had been treated for DM lesions, all the patients concomitantly showed FDG

Fig. 2 In a 76-year-old male with Sweet syndrome, whole-body FDG PET maximum projection and cross-sectional images showed FDG-avid (SUVmax 2.1) lymphadenopathy in the both axillary and hilar regions and in the both external iliac and left inguinal regions (arrows). The biopsy of the left inguinal lymph node revealed follicular lymphoma. In addition, focal intensive FDG uptake (SUVmax 5.0) was also seen in the lower part of gastric corpus (arrowhead), which was later diagnosed as gastric cancer by endoscopic biopsy.
uptakes predominantly in the proximal muscles. One of the previous studies showed FDG-avid various malignant neoplasms in 17 (22%) patients among the total of 75 DM patients [39]. Another study showed FDG-avid various malignant neoplasms in 7 (12%) patients among the total of 55 DM patients [36, 41]. One of our cases showed a combination of DM, interstitial pneumonia and lung cancer (Fig. 5). While it is well-known that DM often coexists with interstitial pneumonia, the rate of occurrence of such a combination is only 0.47%, and only 10 cases in total have been reported in Japan in the past 25 years [38].
Other skin diseases classified as potential PD

Some other cutaneous diseases/symptoms could be associated with underlying neoplasms, but with less associative strength than PD earlier described [43–49] (Table 2).

Lichen planus is an immune-mediated disease which affects skin and mucous membranes and most frequently develops between the ages of 30 and 60 years. On the skin, it usually appears as purplish, itchy, flat bumps that develop over several weeks. In the mouth, vagina and other areas covered by a mucous membrane, it forms lacy white patches, sometimes with painful sores. It has been reported to be associated with a variety of disorders including different malignancies [46]. To our knowledge, there is no case report of FDG-avid neoplasms on FDG PET/CT in a patient with lichen planus. However, we have experienced a case of FDG-avid thymic carcinoma in a patient with lichen planus (Fig. 6).

Herpes zoster may result from reactivation of latent virus in patients with immune system depression or dysfunction associated with underlying malignancy [47–50]. Increased risk of lymphoid malignancy in patients with herpes zoster

Table 2  Other skin diseases classified as potential paraneoplastic dermatoses

| Potential paraneoplastic dermatoses | Associated neoplasms |
|-------------------------------------|----------------------|
| Pityriasis rotunda                  | Hepatocellular, gastric and oesophageal carcinoma, prostate cancer, chronic lymphocytic leukemia and multiple myeloma |
| Palmoplantar keratoderma            | Oral or esophageal carcinomas |
| Pyoderma gangrenosum                | Myelodysplastic syndrome, myeloma, paraproteinemia (IgA) and leukemia |
| Acquired ichthyosis                 | Lymphoproliferative disorders |
| Scleromyxedema                      | Myeloma, lymphoma and leukemia |
| Papulonerythroderma                 | Malignant lymphoma |
| Lichen planus                       | Thymoma, A variety of malignancy |
| Herpes zoster                       | Lymphoid malignancy |
| Chronic itch                        | Lymphoma and leukemia |
| Chronic itch                        | Non-small cell lung carcinoma |
also is reported [47]. Active herpes zoster lesions including lymphadenopathy show FDG uptake on FDG PET/CT, and may mimic lymph node metastasis in patients with malignancy [48–50]. We have experienced such a case in a patient with breast cancer (Fig. 7).

Although chronic itch (pruritus) is just symptom, it is the most common cutaneous symptom experienced by patients with various malignancies, such as hematological malignancies, bile duct/gallbladder carcinomas and liver carcinomas [45]. The presence of symptom of chronic itch occasionally has been documented in patients with these FDG-avid malignant lesions [51].

Skin involvement of malignant neoplasms mimicking benign cutaneous diseases

The skin can be directly involved in malignancies, with the presence of tumor cells caused by direct tumor extension or metastasis, which may mimic some benign cutaneous diseases [4, 5]. Local skin involvement of malignant neoplasms has been reported in patients with gastric, breast, lung, and uterine cancers [4, 5]. Primary cutaneous lymphomas without involvement of lymph nodes, bone marrow or viscera are a heterogeneous group of lymphoproliferative neoplasms, and may mimic erythroderma or panniculitis [52–57]. Sixty five % of primary cutaneous lymphomas originate from mature T lymphocytes, 25% from mature B cells and the remaining part comprises neoplasms of natural killer cells [52–57]. They include mycosis fungoides, Sézary syndrome, primary cutaneous peripheral T cell lymphoma, primary cutaneous anaplastic large cell lymphoma, subcutaneous panniculitis-like T cell lymphoma, extra-nodal NK/T cell lymphoma, and nasal-type, etc. Mycosis fungoides is the commonest of a group of conditions known as cutaneous T cell lymphomas, and may progress very slowly. Most affected individuals initially develop skin lesions called patches, which are flat, scaly, pink or red areas on the skin that can be itchy, which may mimic psoriasis or other inflammatory cutaneous diseases. Affected individuals of mycosis fungoides have an increased risk of developing another lymphoma or other type of cancer.
Only a few studies and case reports evaluate the potential role of FDG PET/CT in diagnosing primary cutaneous lymphomas [52–57]. Several studies indicate that FDG PET/CT is more accurate than CT in detecting both cutaneous and extra-cutaneous diseases of T cell lymphomas including mycosis fungoides [52–54]. We have experienced a total of 8 patients with primary cutaneous lymphomas (including 2 patients of mycosis fungoides), all of which showed FDG-avid cutaneous lesions (Fig. 8).

**Conclusion**

PD can be clinical markers for underlying neoplasms. Recognition of PD and the following searching may lead to the diagnosis of internal malignant neoplasms including early stage ones. This article represented several cases of FDG-avid neoplasms in PD patients in our ten-year experiences, and reviewed the well-known and/or relatively common PD and their associated neoplasms, and the previously reported cases of FDG-avid associated neoplasms in these patients. FDG PET/CT can be expected as an excellent imaging modality for searching and detection of various underlying neoplasms in PD patients, while further accumulation and evaluation of the cases of FDG-avid-associated neoplasms in these patients are needed.
Fig. 8 A 64-year-old male suffered rash-like skin redness, slightly raised or scaly round patches on the skin of the face, trunk and extremities. The biopsy of the skin lesion revealed the diagnosis of cutaneous peripheral T cell lymphoma. Whole-body FDG PET maximum projection and cross-sectional images showed FDG uptake (SUVmax 4.5) in the systemic skin lesions (arrows).

Declarations

Conflict of interest  The author declares no conflict of interest.

Ethical approval All procedures performed in F-18-FDG PET/CT examination were in accordance with the ethical standards of the institutional committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. A written informed consent form was signed by all patients, which included the permission of the use of clinical information and images to be reported in the medical presentation or journal, with hiding and stripping of personally identifiable information.

Informed consent This retrospective review was approved by our institutional review board, and the requirement for written informed consent was waived for retrospective data collection.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Sheikhbahaei S, Marcus CV, Fragomeni RS, Rowe SP, Javadi MS, Solnes LB. Whole-Body F-18-FDG PET and F-18-FDG PET/CT in patients with suspected paraneoplastic syndrome: a systematic review and meta-analysis of diagnostic accuracy. J Nucl Med. 2017;58:1031–6.
2. Kristensen SB, Hess S, Petersen H, Høilund-Carlsen PF. Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients. Eur J Nucl Med Mol Imaging. 2015;42:2056–63.
3. Berner U, Menzel C, Rinne D, Kriener S, Hamscho N, Döbert N, et al. Paraneoplastic syndromes: detection of malignant tumors using F-18-FDG-PET. Q J Nucl Med Mol Imaging. 2006;54:745–62.
4. Chung VQ, Moschella SL, Zembowicz A, Liu V. Clinical and pathologic findings of paraneoplastic dermatoses. J Am Acad Dermatol. 2006;54:745–62.
5. Da Silva JA, MesquitaKde C, Igreja AC. Paraneoplastic cutaneous manifestations: concepts and updates. An Bras Dermatol. 2013;88:9–22.
6. Yuste-Chaves M, Unamuno-Pérez P. Cutaneous alerts in systemic malignancy: part I. Actas Dermosifiliogr. 2013;104:285–98.
7. Wick MR, Patterson JW. Cutaneous paraneoplastic syndromes. Semin Diagn Pathol. 2019;36:211–28.
8. Didona D, Fania L, Didona B, Eming R, Hertl M, Di Zenzo G. Paraneoplastic dermatoses: a brief general review and an extensive analysis of paraneoplastic pemphigus and paraneoplastic dermatomyositis. Int J Mol Sci. 2020;21:2178. https://doi.org/10.3390/ijms21062178.
9. Laura Rodríguez P, James Yurgaky S, William Otero R, Faizal M. A review of paraneoplastic syndromes in gastrointestinal tumors. Rev Colomb Gastroenterol. 2017;32:226–40.
10. Matono S. Malignant acanthosis nigricans with esophageal cancer. Esophagus. 2009;6:127–31.
11. Yu Q, Xiu-Li L, Ji G, Wang Y, Gong Y, Xu H. Malignant acanthosis nigricans: an early diagnostic clue for gastric adenocarcinoma. World J Surg Oncol. 2017;15:208. https://doi.org/10.1186/s12957-017-1274-5.
12. Costa MC, Martinez NS, Belicha MG, Leal F. Acanthosis nigricans and “tripe palm” as paraneoplastic manifestations of metastatic tumor. An Bras Dermatol. 2012;87:498–500.
13. Arellano J. Malignant acanthosis nigricans as a paraneoplastic manifestation of metastatic breast cancer. Int J Womens Dermatol. 2019;5:183–6.
14. Kubicka-Wolkowska J, Debska-Szmich S, Lisik-Habib M, Noweta M, Potemski P. Malignant acanthosis nigricans associated with prostate cancer: a case report. BMC Urol. 2014;14:1–4.
15. Reiter P, Porges L, Thomas J. Leser-Trélat sign presentation with mediastinal squamous cell carcinoma. J Am Osteopathic Coll Dermatol. 2015;33–34. https://cdn.ymaws.com/www.aoodc.org/resource/resmgr/jaoodc.
16. Rüßler F, Goetzte S, Elsner P. Acrokeratosis paraneoplastica (Bazex syndrome)—a systematic review on risk factors, diagnosis, prognosis and management. J Eur Acad Dermatol Venereol. 2017;31:119–1136.
17. Nguyen S, Grosber M, Gutermuth J. Acrokeratosis can be a warning sign of an underlying malignancy. Eur J Case Rep Intern Med. 2019. https://doi.org/10.12890/2019_001108.
18. Aoshima Y, Karayama M, Sagisaka S, Yasui H, Hozumi H, Suzuki Y. Synchronous occurrence of Bazex syndrome and remitting seronegative symmetrical synovitis with pitting edema syndrome in a patient with lung cancer. Intern Med. 2019;58:3267–71.
19. Menenakos C, Braumann C, Hartmann J, Jacobi CA. Retropertioneal Castleman’s tumor and paraneoplastic pemphigus: report of a case and review of the literature. World J Surg Oncol. 2007;28(5):45. https://doi.org/10.1186/1477-7819-5-45.
20. Liu QY, Chen MC, Chen XH, Gao M, Hu HJ, Li HG. Imaging characteristics of abdominal tumor in association with paraneoplastic pemphigus. Eur J Dermatol. 2011;21:83–8.
21. Xiao L, Zhu HM, Li L. Castleman’s disease. Large retroperitoneal Castleman’s tumor and paraneoplastic pemphigus: a case report of a patient with lung cancer. Intern Med. 2019;58:3267–71.
22. Dhall VS, Passah A, Rana N, Arora S, Mallick S, Kumar R. Paraneoplastic pemphigus as a first sign of metastatic retroperitoneal inflammatory myofibroblastic tumor: F-18-FDG PET/CT findings. Rev Esp Med Nucl Imagen Mol. 2016;35:260–2.
23. Khoshbin T, Loser C, Dippel E. Paraneoplastic skin diseases. Internist. 2019;60:775–82.
24. Tamura A, Ogasawara T, Fujii Y, Kaneko H, Nakayama A. Glucagonoma with necrotic migratory erythema: metabolic profile and detection of ballelicin activation of DAXX gene. J Clin Endocrinol Metab. 2018;103:2417–23.
25. Stephen P, Stone SP, Lucinda S, Buescher LS. Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol. 2005;23:301–6.
26. Fujimoto N, Kito K, Yoshida T, Tanaka T. Primary cutaneous CD4/CD8−/− TCRβ+ T-cell lymphoma. Acta Derm Venereol. 2015;95:106–7.
27. Vulinik AJE, Huinink DB. Acquired hypertrichosis lanuginosa: a rare cutaneous paraneoplastic syndrome. J Clin Oncol. 2007;25:1625–6.
28. Shah M, Sachdeva M, Gefri A, Jfri A. Paraneoplastic pyoderma gangrenosum in solid organ malignancy: a literature review. Int J Dermatol. 2020;59:154–8.
29. Yang TH, Hu CH, Tsai HH. Pyoderma gangrenosum preceding the onset of extranodal natural killer/T-cell lymphoma. Medicine (Baltimore). 2016;95:4997.
30. Dong A, Wang Y, Gao L, Zuo C. F-18-FDG PET/CT findings in a patient with Sweet syndrome associated with myelodysplastic syndrome. Clin Nucl Med. 2013;38:454–7.
31. Krug B, Sonet A, Pirson AS, Mahy N, Bosly A, Borght TV. FDG PET utility in paraneoplastic Sweet syndrome. Clin Nucl Med. 2004;29:91–2.
32. Deng S, Zhang B, Sui X, Sang S, Zhang W. Elevated F-18-FDG uptake in skeletal muscles rather than cutaneous foci in a patient with Sweet’s syndrome. Clin Nucl Med. 2016;41:938–40.
33. Khanha U, Galimberti F, Li Y, Fernandez AP. Dermatomyositis and malignancy: should all patients with dermatomyositis undergo malignancy screening? Ann Transl Med. 2021;9:432.
34. Leatham H, Schadt C, Chisolm S, Fretwell D, Chung L, Jeffrey P, et al. Evidence supports blind screening for internal malignancy in dermatomyositis: data from 2 large US dermatology cohorts. Medicine (Baltimore). 2018;97:9639.
35. Oldroyd AGS, Allard AB, Callen JP, Chinoy H, Chung L, Fiorentino D, et al. A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford). 2021;60:2615–28.
36. Arai-Okuda H, Norikane T, Yamamoto Y, Mitamura K, Fujiwara T, Fujioka T. Paraneoplastic dermatoses: a brief general review and an extensive analysis of paraneoplastic pemphigus and Paraneoplastic pemphigoid. Autoimmun Rev. 2012;11(8):783–9.
37. van Heerden T, Webb MJ, Barrett CL. Pityriasis rotunda as an occult malignancy in patients with dermatomyositis. Heliyon. 2020;6: e03707. https://doi.org/10.1016/j.heliyon.2020.e03707.
38. Mahmood S, Martínez de Llano SR. F-18-FDG PET detection of unknown primary malignancy in dermatomyositis. Clin Nucl Med. 2012;37:204–5.
39. Selva-O’Callaghan A, Grau JM, Gámez-Cenzano C, Vicalloler-Palacín A, Martínez-Gómez X, Trallero-Araguás E, et al. A rare combination of dermatomyositis, interstitial pneumonia, and lung cancer in a patient treated with immunosuppressive therapy and chemotherapy. Intern Med. 2018;57:849–53.
40. Li X, Tan H. Value of F-18-FDG PET/CT in patients with polymyositis/dermatomyositis: correlation with serum muscle enzymes. Eur J Hybrid Imaging. 2020;4:14. https://doi.org/10.1186/s41824-020-00084-w.
41. Daido W, Yamasaki M, Morio Y, Funaiishi K, Ishiyama S, Deganichi N, et al. A rare combination of dermatomyositis, interstitial pneumonia, and lung cancer in a patient treated with immunosuppressive therapy. Intern Med. 2018;57:849–53.
42. Palacín A, Martínez-Gómez X, Trallero-Araguás E, et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med. 2010;123:558–62.
43. Suh KJ, Park JK, Cho S, Park H, Baek HW, Lee K, et al. Dermatomyositis in a patient with cholangiocarcinoma detected by an F-18-fluoro-deoxyglucose positron emission tomography-computed tomography scan. Cancer Res Treat. 2016;48:848–52.
44. Teraki Y, Aso Y, Sato Y. High incidence of internal malignancy in papuloerythroderma of Otfuji: a case series from Japan. Dermatology. 2012;224:5–9.
45. van Heerden T, Webb MJ, Barrett CL. Pityriasis rotunda is a paraneoplastic finding in two patients with multiple myeloma. Clin Exp Dermatol. 2014;39:734–7.
46. Hayashi A, Shiono H, Okumura M. Thymoma accompanied by lichen planus. Interact Cardiovasc Thorac Surg. 2008;7:347–8.
47. Choi HG, Zehnder JL, Lee YK, Lim H, Kim M. Increased risk of lymphoid malignancy in patients with herpes zoster: a longitudinal follow-up study using a national cohort. BMC Cancer. 2019;19:1148.
48. Choi EK, Oh JK, Yong-An Chung YA. Herpes zoster mimicking breast cancer with axillary lymph node metastasis on PET/CT. Clin Nucl Med. 2015;40:572–3.
49. Fujioka T, Yokoyama K, Mori M, Yashima Y, Yamaga E, Kubota K, et al. Active herpes zoster mimicking worsening of axillary lymph node metastases of breast cancer after chemotherapy on F-18-fluorodeoxyglucose positron-emission tomography/computed tomography. Diagnostics (Basel). 2021;11:1085.
50. Harashima K, Watanabe S, Okazaki N, Endo D, Uchiyama Y, Kato F, et al. Herpes zoster infection mimicking pelvic lymph node metastasis on FDG-PET/CT in a patient with cervical cancer. Asia Ocean J Nucl Med Biol. 2021;9:183–7.
51. Okamura I, Raine Tatara R, Takashi IT. Paraneoplastic refractory prurigos in a Hodgkin lymphoma patient. Jpn J Clin Oncol. 2016;46:1179–80.
52. Xu L, Pang H, Jin Zhu J, Chen X, Guan L. Mycosis fungoides staged by F-18-fluoro-deoxyglucose positron emission tomography/computed tomography: case report and review of literature. Medicine. 2016;95:e5044.
53. Jiang M, Zhao L, Zheng J, Zhang J, Chen P, Zhou W. Report of eleven patients of subcutaneous panniculitis-like T-Cell lymphoma: Clinicopathologic features, F-18-FDG PET/CT findings and outcome. Front Oncol. 2021;11: 650822.
54. Kalender E, Yilmaz M, Erkiliç S, Yilmaz M, Celen Z. Bilateral cutaneous diffuse large B-cell lymphoma on FDG PET/CT. Clin Nucl Med. 2011;36:e153–5.
55. Dejust S, Morland D, Durot E, Grange F, Papathanassiou D. F-18-FDG PET/CT in primary cutaneous diffuse large B-cell lymphoma leg type. Clin Nucl Med. 2020;45:403–4.
56. Mandava A, Koppula V, Wortsman X, Catalano O, Alfageme F. The clinical value of imaging in primary cutaneous lymphomas: role of high resolution ultrasound and PET-CT. Br J Radiol. 2019;92:20180904. https://doi.org/10.1259/bjr.20180904.
57. Kim JS, Jeong YJ, Sohn MH, Lim ST, Kim DW, Jeong HJ, et al. Before and after treatment F-18-FDG PET/CT images in a patient with cutaneous T-cell lymphoma. Eur J Nucl Med Mol Imaging. 2010;37:1995. https://doi.org/10.1007/s00259-010-1548-4 (Epub 2010 Jul 24).

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.